ArticleJournal of clinical microbiology2014
Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- Distribution of Human Papillomavirus Genotypes in Real-World Cervical Self-Collected Scrapings From the Dutch Cervical Cancer Screening Program.Journal of medical virology · 2025Article
- The necessity and challenges of human papillomavirus testing for men.Frontiers in cellular and infection microbiology · 2025Review
- Evolving HPV diagnostics: current practice and future frontiers.Frontiers in cellular and infection microbiology · 2025Review
- The application of deep learning based diagnostic system to cervical squamous intraepithelial lesions recognition in colposcopy images.Scientific reports · 2020Article
- Article
- Cervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China.Cancer management and research · 2018Article
- Increased proportions of HIV-infected women met cervical cancer screening guideline in 2016.International journal of women's health · 2018Article
- Role of high-risk human papillomavirus in the etiology of oral and oropharyngeal cancers in Thailand: A case-control study.SAGE open medicine · 2018Article
- Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers.Cancers · 2016Review
- The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening.Journal of clinical microbiology · 2016Article
- HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions.Journal of Cancer · 2016Review
- Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.BMC infectious diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.